|
|
DSpace at RU >
Search Results
Results 1-45 of 45.
Item hits:
| Full Text | Issue Date | Title | Author(s) |  | 2011 | High-dose rifampicin: how do we proceed? | Boeree, M.J.; Plemper van Balen, G.; Aarnoutse, R. |
| | 2011 | Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge | Ingen, J. van; Aarnoutse, R.E.; Vries, G. de; Boeree, M.J.; Soolingen, D. van |
| | 2011 | Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? | Ingen, J. van; Aarnoutse, R.E.; Donald, P.R.; Diacon, A.H.; Dawson, R.; Plemper van Balen, G.; Gillespie, S.H.; Boeree, M.J. |
| | 2011 | Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach. | Pranger, A.D.; Alffenaar, J.W.C.; Aarnoutse, R.E. |
| | 2011 | The complexity of the adherence-response relationship in tuberculosis treatment: why are we still in the dark and how can we get out? | Boogaard, J. van den; Boeree, M.J.; Kibiki, G.S.; Aarnoutse, R.E. |
| | 2011 | Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience | Pranger, A.D.; Altena, R. van; Aarnoutse, R.E.; Soolingen, D. van; Uges, D.R.A.; Kosterink, J.G.W.; Werf, T.S. van der; Alffenaar, J.W.C. |
| | 2011 | Plasma drug activity assay for treatment optimization in tuberculosis patients | Heysell, S.K.; Mtabho, C.; Mpagama, S.; Mwaigwisya, S.; Pholwat, S.; Ndusilo, N.; Gratz, J.; Aarnoutse, R.E.; Kibiki, G.S.; Houpt, E.R. |
| | 2011 | Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania | Boogaard, J. van den; Semvua, H.H.; Ingen, J. van; Mwaigwisya, S.; Laan, T. van der; Soolingen, D. van; Kibiki, G.S.; Boeree, M.J.; Aarnoutse, R.E. |
| | 2011 | Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study | Boogaard, J. van den; Lyimo, R.A.; Boeree, M.J.; Kibiki, G.S.; Aarnoutse, R.E. |
 | 2011 | The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program. | Burger, D.M.; Teulen, M.J.A.; Eerland, J.; Harteveld, A.; Aarnoutse, R.E.; Touw, D. |
| | 2011 | Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis | Pranger, A.D.; Kosterink, J.G.W.; Altena, R. van; Aarnoutse, R.E.; Werf, T.S. van der; Uges, D.R.A.; Alffenaar, J.W.C. |
 | 2010 | Assessment of antibacterial sale by using the Anatomic Therapeutic Chemical classification and defined daily dose methodology in Moshi Municipality, Northern Tanzania. | Boogaard, J. van den; Semvua, H.H.; Boeree, M.J.; Aarnoutse, R.E.; Kibiki, G.S. |
| | 2010 | Antituberculosis drug-induced hepatotoxicity is uncommon in Tanzanian hospitalized pulmonary TB patients. | Tostmann, A.; Boogaard, J. van den; Semvua, H.; Kisonga, R.; Kibiki, G.S.; Aarnoutse, R.E.; Boeree, M.J. |
| | 2010 | Xanthine oxidase inhibition by allopurinol increases in vitro pyrazinamide-induced hepatotoxicity in HepG2 cells. | Tostmann, A.; Aarnoutse, R.E.; Peters, W.H.M.; Richard, P.N.; Boeree, M.J. |
| | 2010 | Sale of fluoroquinolones in northern Tanzania: a potential threat for fluoroquinolone use in tuberculosis treatment. | Boogaard, J. van den; Semvua, H.H.; Boeree, M.J.; Aarnoutse, R.E.; Kibiki, G.S. |
| | 2010 | Implications of the global increase of diabetes for tuberculosis control and patient care. | Ruslami, R.; Aarnoutse, R.E.; Alisjahbana, B.; Ven, A.J.A.M. van der; Crevel, R. van |
| | 2010 | Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. | Ruslami, R.; Nijland, H.M.J.; Adhiarta, I.G.; Kariadi, S.H.; Alisjahbana, B.; Aarnoutse, R.E.; Crevel, R. van |
| | 2010 | Childhood tuberculosis in the Kilimanjaro region: lessons from and for the TB programme. | Mtabho, C.M.; Irongo, C.F.; Boeree, M.J.; Aarnoutse, R.E.; Kibiki, G.S. |
| | 2009 | New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. | Boogaard, J. van den; Kibiki, G.S.; Kisanga, E.R.; Boeree, M.J.; Aarnoutse, R.E. |
| | 2009 | International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. | Bruggemann, R.J.M.; Touw, D.J.; Aarnoutse, R.E.; Verweij, P.E.; Burger, D.M. |
| | 2009 | Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. | Alffenaar, J.W.C.; Altena, R. van; Bokkerink, H.J.; Luijckx, G.J.R.; Soolingen, D. van; Aarnoutse, R.E.; Werf, T.S. van der |
| | 2009 | Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. | L'homme, R.F.A.; Nijland, H.M.J.; Gras, L.; Aarnoutse, R.E.; Crevel, R. van; Boeree, M.J.; Brinkman, K.; Prins, J.M.; Juttmann, J.R.; Burger, D.M. |
| | 2009 | Community vs. facility-based directly observed treatment for tuberculosis in Tanzania's Kilimanjaro Region. | Boogaard, J. van den; Lyimo, R.; Irongo, C.F.; Boeree, M.J.; Schaalma, H.; Aarnoutse, R.E.; Kibiki, G.S. |
| | 2008 | Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. | Wyen, C.; Fuhr, U.; Frank, D.; Aarnoutse, R.E.; Klaassen, T.; Lazar, A.; Seeringer, A.; Doroshyenko, O.; Kirchheiner, J.C.; Abdulrazik, F.; Schmeisser, N.; Lehmann, C.; Hein, W.; Schomig, E.; Burger, D.M.; Fatkenheuer, G.; Jetter, A. |
| | 2008 | Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity. | Tostmann, A.; Boeree, M.J.; Peters, W.H.M.; Roelofs, H.M.J.; Aarnoutse, R.E.; Ven, A.J.A.M. van der; Dekhuijzen, P.N.R. |
| | 2008 | Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. | Tostmann, A.; Boeree, M.J.; Aarnoutse, R.E.; Lange, W.C.M. de; Ven, A.J.A.M. van der; Dekhuijzen, R. |
| | 2008 | A step-wise approach to find a valid and feasible method to detect non-adherence to tuberculosis drugs. | Ruslami, R.; Crevel, R. van; Berge, E van de; Alisjahbana, B.; Aarnoutse, R.E. |
| | 2008 | Therapeutic drug monitoring of voriconazole. | Bruggemann, R.J.M.; Donnelly, J.P.; Aarnoutse, R.E.; Warris, A.; Blijlevens, N.M.A.; Mouton, J.W.; Verweij, P.E.; Burger, D.M. |
| | 2008 | High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. | Nijland, H.M.J.; L'homme, R.F.A.; Rongen, G.A.P.J.M.; Uden, P. van; Crevel, R. van; Boeree, M.J.; Aarnoutse, R.E.; Koopmans, P.P.; Burger, D.M. |
| | 2007 | Determination of emtricitabine in human plasma using HPLC with fluorometric detection. | Droste, J.A.H.; Aarnoutse, R.E.; Burger, D.M. |
| | 2007 | Caffeine and muscle cramps: a stimulating connection. | Molema, M.; Dekker, M.C.J.; Voermans, N.C.; Engelen, B.G.M. van; Aarnoutse, R.E. |
| | 2007 | Het draait allemaal om de pH. Intoxicaties met salicylaten | Kanter, C.T.M.M. de; Kramers, C.; Aarnoutse, R.E. |
| | 2007 | Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. | Nijland, H.M.J.; Ruslami, R.; Suroto, A.J.; Burger, D.M.; Alisjahbana, B.; Crevel, R. van; Aarnoutse, R.E. |
| | 2007 | Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. | Ruslami, R.; Nijland, H.M.J.; Alisjahbana, B.; Parwati, I.; Crevel, R. van; Aarnoutse, R.E. |
| | 2006 | Ziekenhuisapotheker adviseert bij intoxicatie. Lithiumtabletten met gereguleerde afgifte. | Kramers, C.; Aarnoutse, R.E.; Jansman, F.G.A. |
| | 2006 | Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis. | Ruslami, R.; Nijland, H.M.J.; Aarnoutse, R.E.; Alisjahbana, B.; Soeroto, A.Y.; Ewalds, S.; Crevel, R. van |
| | 2006 | Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. | Nijland, H.M.J.; Ruslami, R.; Stalenhoef, J.E.; Nelwan, E.J.; Alisjahbana, B.; Nelwan, R.H.; Ven, A.J.A.M. van der; Danusantoso, H.; Aarnoutse, R.E.; Crevel, R. van |
| | 2005 | Met spiegels en vensters meer zicht. Therapeutic drug monitoring van antiretrovirale middelen. | Burger, D.M.; Lee, M.J. van der; Droste, J.A.H.; L'homme, R.F.A.; Porte, C.J.L. la; Aarnoutse, R.E. |
| | 2005 | Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. | Verweij-van Wissen, C.P.W.G.M.; Aarnoutse, R.E.; Burger, D.M. |
| | 2005 | Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. | Aarnoutse, R.E.; Kleinnijenhuis, J.; Koopmans, P.P.; Touw, D.J.; Wieling, J.; Hekster, Y.A.; Burger, D.M. |
| | 2005 | Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers. | Porte, C.J.L. la; Verweij-van Wissen, C.P.W.G.M.; Ewijk, N. van; Aarnoutse, R.E.; Koopmans, P.P.; Reiss, P.; Stek Jr, M.; Hekster, Y.A.; Burger, D.M. |
| | 2004 | The effect of nevirapine on the pharmacokinetics of indinavir/ritonavir 800/100 mg BID | Burger, D.M.; Prins, J.M.; Ende, M.E. van der; Aarnoutse, R.E. |
| | 2004 | Pharmacokinetics of indinavir/ritonavir (800/100 mg twice a day) combined with efavirenz in HIV-infected patients. | Aarnoutse, R.E.; Brinkman, K.; Benetucci, J.; Begovac, J.; Stek Jr, M.; Burger, D.M. |
| | 2003 | Application of pharmacokinetics to improve antiretroviral treatment | Aarnoutse, R.E. |
| | 1995 | Verdamping van water uit medicatiecassettes gevuld met 5-fluorouracil | Aarnoutse, R.E.; Burger, D.M.; Akkers, M.R.J.; Bakker, J.H. |
1
|
